Base Editing (BE4max) for IL10RA c.506T>C (p.Ile169Thr) in Monogenic very-early-onset inflammatory bowel disease due to IL10RA deficiency

Base Editing (BE4max) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Monogenic very-early-onset inflammatory bowel disease due to IL10RA deficiency targeting the IL10RA c.506T>C (p.Ile169Thr) variant (Pathogenic, missense variant, non-coding transcript variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct biallelic loss-of-function variants in IL10RA at the intestinal immune-cell and epithelial-cell loci to restore IL-10 signalling and achieve permanent remission of very-early-onset inflammator. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: IL10RA NM_001558.4(IL10RA):c.506T>C (p.Ile169Thr) is classified as Pathogenic (ClinVar variation ID 943905). Molecular consequence: missense variant, non-coding transcript variant. Protein change: I169T. 2. Epidemiology: IL10RA-deficient very-early-onset IBD is an ultra-rare autosomal recessive monogenic form of inflammatory bowel disease, typically presenting in the first months of life with severe enterocolitis, perianal disease, and failure to thrive. Cohort and regional data suggest that monogenic VEO-IBD consti 3. Standard of care: Conventional IBD therapies (steroids, immunomodulators, biologics such as anti-TNF or vedolizumab) rarely induce sustained remission in IL10RA-deficient VEO-IBD; most patients remain dependent on parenteral nutrition, have persistent disease activity, and often require surgery. Multiple cohort studi 4. Pipeline: For IL10RA/B monogenic IBD, there are currently no registered in vivo gene therapy or gene-editing clinical trials identified in public registries; HSCT is used as a standard curative cellular therapy in specialized centers. Gene therapy and gene editing for intestinal and immune targets are at prec 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting IL10RA c.506T>C (p.Ile169Thr) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.